Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Apr 17, 2000
INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening targets, utilizing Arena's proprietary CART™...
Jan 31, 2000
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have entered into a collaboration involving Arena's proprietary CART™ Technology...
Jan 19, 2000
SAN DIEGO, Jan. 19 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, announced today that it was awarded a one-year, $106,000 Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The Company will ...
Sep 15, 1999
SAN DIEGO, Sept. 15 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced a collaboration involving the application of Arena's constitutive activation technology to three Neurocrine orphan G protein-coupled recepto...
Apr 17, 1999
SAN DIEGO, May 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, announced the successful completion of a Phase I clinical investigation of the safety and pharmacokinetics of T-82 in healthy, elderly volunteers. This was a first-in-man study ...
Feb 22, 1999
SAN DIEGO, Feb. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, has announced the successful completion of a private offering through the sale of its Series D Preferred Stock. Arena had intended to raise $10 Million through this offer...
= add release to Briefcase